What is it about?
This is a very detailed market survey sort of review paper about how India has made its name in the pharmaceutical industry and is entering biosimilars market which is kind of difficult as India is mostly known for making generic drugs or copy-drugs. This scenario is changing and would soon take a massive turn
Featured Image
Why is it important?
It gives us a perspective on where India stands in the health sector and how it can make its way further from the survey that has already been taken care of
Perspectives
The amount of details that has been included and the depth of information is very well put and is surely a must-read for anyone starting off in pharmaceutical industry
Sagnik Mitra
Indian Institute of Technology Indore
Read the Original
This page is a summary of: Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics, Vaccines, January 2023, MDPI AG,
DOI: 10.3390/vaccines11010110.
You can read the full text:
Contributors
The following have contributed to this page
